164 related articles for article (PubMed ID: 11590530)
1. Effect of prior nucleoside use on the two-year virological response to an initial protease inhibitor regimen in HIV-infected patients.
Kazanjian P; Tashima K; Hollander T; Kaul D
HIV Clin Trials; 2001; 2(3):213-8. PubMed ID: 11590530
[TBL] [Abstract][Full Text] [Related]
2. Incidence and predictors of virologic failure of antiretroviral triple-drug therapy in a community-based cohort.
Paris D; Ledergerber B; Weber R; Jost J; Flepp M; Opravil M; Ruef C; Zimmerli S
AIDS Res Hum Retroviruses; 1999 Dec; 15(18):1631-8. PubMed ID: 10606086
[TBL] [Abstract][Full Text] [Related]
3. The insufficient suppression of viral load by saquinavir hard gel is reversible: a retrospective cohort study.
Jensen-Fangel S; Kirk O; Blaxhult A; Gerstoft J; Pedersen C; Black FT; Lundgren JD; Obel N
HIV Clin Trials; 2001; 2(2):122-7. PubMed ID: 11590520
[TBL] [Abstract][Full Text] [Related]
4. Three-year effectiveness of highly active antiretroviral treatment in the Luxembourg HIV cohort.
Servais J; Schmit JC; Arendt V; Lambert C; Staub T; Robert I; Fontaine E; Plesséria JM; Burgy C; Kirpach P; Schneider F; Hemmer R
HIV Clin Trials; 2000; 1(2):17-24. PubMed ID: 11590494
[TBL] [Abstract][Full Text] [Related]
5. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
6. Combination therapy with indinavir, ritonavir, and delavirdine and nucleoside reverse transcriptase inhibitors in patients with HIV/AIDS who have failed multiple antiretroviral combinations.
Grodesky M; Acosta EP; Fujita N; Mason S; Gerber JG
HIV Clin Trials; 2001; 2(3):193-9. PubMed ID: 11590527
[TBL] [Abstract][Full Text] [Related]
7. A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial.
MacArthur RD; Novak RM; Peng G; Chen L; Xiang Y; Hullsiek KH; Kozal MJ; van den Berg-Wolf M; Henely C; Schmetter B; Dehlinger M; ;
Lancet; 2006 Dec; 368(9553):2125-35. PubMed ID: 17174704
[TBL] [Abstract][Full Text] [Related]
8. Evidence of immune reconstitution in antiretroviral drug-experienced patients with advanced HIV disease.
Landay AL; Bettendorf D; Chan E; Spritzler J; Schmitz JL; Bucy RP; Gonzalez CJ; Schnizlein-Bick CT; Evans T; Squires KE; Phair JP
AIDS Res Hum Retroviruses; 2002 Jan; 18(2):95-102. PubMed ID: 11839142
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy.
Pavie J; Porcher R; Torti C; Medrano J; Castagna A; Valin N; Rusconi S; Ammassari A; Ghosn J; Delaugerre C; Molina JM;
J Antimicrob Chemother; 2011 Oct; 66(10):2372-8. PubMed ID: 21821627
[TBL] [Abstract][Full Text] [Related]
10. Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first-line boosted highly active antiretroviral therapy based on protease inhibitors: meta-regression analysis of 12 clinical trials in 5168 patients.
Hill A; Sawyer W
HIV Med; 2009 Oct; 10(9):527-35. PubMed ID: 19785663
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of nucleoside reverse transcriptase inhibitor-sparing salvage therapy for multidrug-resistant HIV-1 infection based on new-class and new-generation antiretrovirals.
Imaz A; Llibre JM; Mora M; Mateo G; Camacho A; Blanco JR; Curran A; Santos JR; Caballero E; Bravo I; Gayá F; Domingo P; Rivero A; Falcó V; Clotet B; Ribera E
J Antimicrob Chemother; 2011 Feb; 66(2):358-62. PubMed ID: 21172789
[TBL] [Abstract][Full Text] [Related]
12. Switch to efavirenz in a protease inhibitor-containing regimen.
Knechten H; Stürner KH; Höhn C; Braun P
HIV Clin Trials; 2001; 2(3):200-4. PubMed ID: 11590528
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of boosted protease inhibitor-based regimens in HIV type 1-infected patients who experienced virological failure with NNRTI-based antiretroviral therapy in a resource-limited setting.
Siripassorn K; Manosuthi W; Chottanapund S; Pakdee A; Sabaitae S; Prasithsirikul W; Tunthanathip P; Ruxrungtham K;
AIDS Res Hum Retroviruses; 2010 Feb; 26(2):139-48. PubMed ID: 20156097
[TBL] [Abstract][Full Text] [Related]
14. An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults.
Bartlett JA; Fath MJ; Demasi R; Hermes A; Quinn J; Mondou E; Rousseau F
AIDS; 2006 Oct; 20(16):2051-64. PubMed ID: 17053351
[TBL] [Abstract][Full Text] [Related]
15. Initial therapy with nucleoside reverse transcriptase inhibitor-containing regimens is more effective than with regimens that spare them with no difference in short-term fat distribution: Hippocampe-ANRS 121 Trial.
Duvivier C; Ghosn J; Assoumou L; Soulié C; Peytavin G; Calvez V; Génin MA; Molina JM; Bouchaud O; Katlama C; Costagliola D;
J Antimicrob Chemother; 2008 Oct; 62(4):797-808. PubMed ID: 18641035
[TBL] [Abstract][Full Text] [Related]
16. Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy.
Geretti AM; Smith C; Haberl A; Garcia-Diaz A; Nebbia G; Johnson M; Phillips A; Staszewski S
Antivir Ther; 2008; 13(7):927-36. PubMed ID: 19043927
[TBL] [Abstract][Full Text] [Related]
17. HIV-1 genotype after interruption of non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy and virological response after resumption of the same regimen.
Sungkanuparph S; Kiertiburanakul S; Apisarnthanarak A; Malathum K; Sathapatayavongs B
Int J STD AIDS; 2007 Dec; 18(12):832-4. PubMed ID: 18073016
[TBL] [Abstract][Full Text] [Related]
18. Predictors of long-term immunological outcome in rebounding patients on protease inhibitor-based HAART after initial successful virologic suppression: implications for timing to switch.
Tomasoni LR; Patroni A; Torti C; Paraninfo G; Gargiulo F; Quiros-Roldan E; Uccelli MC; Airò P; Tinelli C; Carosi G; Castelli F;
HIV Clin Trials; 2003; 4(5):311-23. PubMed ID: 14583847
[TBL] [Abstract][Full Text] [Related]
19. Comparison of initial combination antiretroviral therapy with a single protease inhibitor, ritonavir and saquinavir, or efavirenz.
Lucas GM; Chaisson RE; Moore RD
AIDS; 2001 Sep; 15(13):1679-86. PubMed ID: 11546943
[TBL] [Abstract][Full Text] [Related]
20. The use of efavirenz as a part of late rescue antiretroviral treatment.
Manfredi R; Rizzo E; Calza L; Chiodo F
HIV Clin Trials; 2001; 2(5):413-20. PubMed ID: 11673816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]